Biomarker Classifiers for Identifying Susceptible Subpopulations for Treatment Decisions

• Golub TR , SlonimDK, TamayoP et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286(5439) , 531–537 (1999).
   PubMed Web of Science ®Google Scholar
• Whelan T , SawkaC, LevineM et al. Helping patients make informed choices: a randomized trial of a decision aid for adjuvant chemotherapy in lymph node-negative breast cancer. J. Natl Cancer Inst. 95(8) , 581–587 (2003).
   PubMed Web of Science ®Google Scholar
• Zhang H , YuCY, SingerB, XiongM. Recursive partitioning for tumor classification with gene expression microarray data. Proc. Natl Acad. Sci. USA98(12) , 6730–6735 (2001).
   Web of Science ®Google Scholar
• Grothey A . Risk assessment in stage II colon cancer: to treat or not to treat? Oncology24(Suppl. 1) , 1–2 (2010).
   Web of Science ®Google Scholar
• van‘t Veer LJ , DaiH, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature415(6871) , 530–536 (2002).
   PubMed Web of Science ®Google Scholar
• Waldman SA , HyslopT, SchulzS et al. Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer. JAMA 301(7) , 745–752 (2009).
   PubMed Web of Science ®Google Scholar
• Avigan MI . Pharmacogenomic biomarkers of susceptibility to adverse drug reactions: just around the corner or pie in the sky? Personalized Medicine6(1) , 67–78 (2009).
   Web of Science ®Google Scholar
• Lin W -J, Chen JJ. An approach to identify preclinical biomarkers of susceptibility to drug-induced toxicity. Pharmacogenomics12(4) , 493–501 (2011).
   PubMed Web of Science ®Google Scholar
• Hultin-Rosenberg L , JagannathanS, NilssonKC et al. Predictive models of hepatotoxicity using gene expression data from primary rat hepatocytes. Xenobiotica 36(10–11) , 1122–1139 (2006).
   PubMed Web of Science ®Google Scholar
• Fielden MR , EynonBP, NatsoulisG, JarnaginK, BanasD, KolajaKL. A gene expression signature that predicts the future onset of drug-induced renal tubular toxicity. Toxicol. Pathol.33(6) , 675–683 (2005).
   PubMed Web of Science ®Google Scholar
• Adler M , HoffmannD, Ellinger-ZiegelbauerH et al. Assessment of candidate biomarkers of drug-induced hepatobiliary injury in preclinical toxicity studies. Toxicol. Lett. 196(1) , 1–11 (2010).
   PubMed Web of Science ®Google Scholar
• Hoffmann D , AdlerM, VaidyaVS et al. Performance of novel kidney biomarkers in preclinical toxicity studies. Toxicol. Sci. 116(1) , 8–22 (2010).
   PubMed Web of Science ®Google Scholar
• Fielden MR , BrennanR, GollubJ. A gene expression biomarker provides early prediction and mechanistic assessment of hepatic tumor induction by nongenotoxic chemicals. Toxicol. Sci.99(1) , 90–100 (2007).
   PubMed Web of Science ®Google Scholar
• Yang Y , AbelSJ, CiurlionisR, WaringJF. Development of a toxicogenomics in vitro assay for the efficient characterization of compounds. Pharmacogenomics7(2) , 177–186 (2006).
   PubMed Web of Science ®Google Scholar
• Zidek N , HellmannJ, KramerPJ, HewittPG. Acute hepatotoxicity: a predictive model based on focused illumina microarrays. Toxicol. Sci.99(1) , 289–302 (2007).
   PubMed Web of Science ®Google Scholar
• Maggioli J , HooverA, WengL. Toxicogenomic analysis methods for predictive toxicology. J. Pharmacol. Toxicol. Methods53(1) , 31–37 (2006).
   Google Scholar
• Huang J , ShiW, ZhangJ et al. Genomic indicators in the blood predict drug-induced liver injury. Pharmacogenomics J. 10(4) , 267–277 (2010).
   PubMed Web of Science ®Google Scholar
• Bushel PR , HeinlothAN, LiJ et al. Blood gene expression signatures predict exposure levels. Proc. Natl Acad. Sci. USA 104(46) , 18211–18216 (2007).
   PubMed Web of Science ®Google Scholar
• Tsai C -A, Wang S-J, Chen D-T, Chen JJ. Sample size for gene expression microarray experiments. Bioinformatics21(8) , 1502–1508 (2005).
   Web of Science ®Google Scholar
• Lin W -J, Hsueh H-M, Chen JJ. Power and sample size estimation in microarray studies. BMC Bioinformatics11 , 48 (2010).
   PubMed Web of Science ®Google Scholar
• Breiman L . Random forests. Mach. Learn.45(1) , 5–32 (2001).
   Web of Science ®Google Scholar
• Vapnik V . Statistical Learning Theory. John Wiley and Sons, NY, USA, 401–441 (1998).
   Google Scholar
• Guyon I , WestonJ, BarnhillS, VapnikV. Gene selection for cancer classification using support vector machines. Mach. Learn.46(1–3) , 389–422 (2002).
   Web of Science ®Google Scholar
• Dudoit S , FridlyandJ, SpeedTP. Comparison of discrimination methods for the classification of tumors using gene expression data. J. Am. Stat. Assoc.97(457) , 77–87 (2002).
   Web of Science ®Google Scholar
• Tumer K , GhoshJ. Error correlation and error reduction in ensemble classifiers. Connect. Sci.8(3) , 385–404 (1996).
   Google Scholar
• Breiman L . Bagging predictors. Mach. Learn.24(2) , 123–140 (1996).
   Web of Science ®Google Scholar
• Breiman L . Arcing classifiers. Ann. Stat.26(3) , 801–849 (1998).
   Web of Science ®Google Scholar
• Chen JJ , Tsai C-A, Young JF, Kodell RL. Classification ensembles for unbalanced class sizes in predictive toxicology. SAR QSAR Environ. Res.16(6) , 517–529 (2005).
   PubMed Web of Science ®Google Scholar
• McBurney RN , HinesWM, Von Tungeln LS et al. The liver toxicity biomarker study: Phase I design and preliminary results. Toxicol. Pathol.37(1) , 52–64 (2009).
   PubMed Web of Science ®Google Scholar
• Kodell RL , ChenJJ. Is premarket identification of hepatotoxic drugs and sensitive patients possible based on high-dimensional ‘omic‘ data? Pers. Med.7(2) , 171–178 (2010).
   Web of Science ®Google Scholar
• Sawyers CL . The cancer biomarker problem. Nature452 , 548–552 (2008).
   PubMed Web of Science ®Google Scholar
• Simon R . The use of genomics in clinical trial design. Clin. Cancer Res.14(19) , 5984–5993 (2008).
   PubMed Web of Science ®Google Scholar
• Simon R , MaitournamA. Evaluating the efficiency of targeted designs for randomized clinical trials. Clin. Cancer Res.10(20) , 6759–6763 (2004).
   PubMed Web of Science ®Google Scholar
• Wang SJ , O‘NeillRT, HungHM. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharm. Stat.6(3) , 227–244 (2007).
   PubMed Web of Science ®Google Scholar
• Liu A , LiuC, LiQ, YuKF, YuanVW. A threshold sample-enrichment approach in a clinical trial with heterogeneous subpopulations. Clin. Trials7(5) , 537–545 (2010).
   PubMed Web of Science ®Google Scholar
• Jiang W , FreidlinB, SimonR. Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. J. Natl Cancer Inst.99(13) , 1036–1043 (2007).
   Google Scholar
• Simon R , WangSJ. Use of genomic signatures in therapeutics development in oncology and other diseases. Pharmacogenomics J.6(3) , 166–173 (2006).
   PubMed Web of Science ®Google Scholar

Website

• US FDA: guidance for industry-E15 definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073162.pdf
   Google Scholar